stoxline Quote Chart Rank Option Currency Glossary
Twist Bioscience Corporation (TWST)
31.84  2.39 (8.1%)    04-23 10:30
Open: 29.78
High: 31.99
Volume: 212,618
Pre. Close: 29.45
Low: 29.61
Market Cap: 1,820(M)
Technical analysis
2024-04-23 10:21:16 AM
Short term     
Mid term     
Targets 6-month :  38.87 1-year :  43.12
Resists First :  33.28 Second :  36.91
Pivot price 30.92
Supports First :  27.4 Second :  22.8
MAs MA(5) :  29.22 MA(20) :  31.68
MA(100) :  34.25 MA(250) :  25.13
MACD MACD :  -1.6 Signal :  -1.6
%K %D K(14,3) :  33.1 D(3) :  18.6
RSI RSI(14): 48.6
52-week High :  43.2 Low :  11.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TWST ] has closed below upper band by 39.0%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 29.56 - 29.75 29.75 - 29.93
Low: 27.49 - 27.73 27.73 - 27.95
Close: 29.06 - 29.46 29.46 - 29.82
Company Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Headline News

Sun, 21 Apr 2024
Knights of Columbus Asset Advisors LLC Takes Position in Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat

Fri, 19 Apr 2024
First Week of June 21st Options Trading For Twist Bioscience (TWST) - Nasdaq

Thu, 18 Apr 2024
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024 - Business Wire

Mon, 15 Apr 2024
Twist Bioscience Becomes Oversold (TWST) - Nasdaq

Fri, 05 Apr 2024
Despite shrinking by US$135m in the past week, Twist Bioscience (NASDAQ:TWST) shareholders are still up 132 ... - Yahoo Finance

Thu, 04 Apr 2024
Recent 3.3% pullback isn't enough to hurt long-term Twist Bioscience (NASDAQ:TWST) shareholders, they're still up 149% over 1 year - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Diagnostics & Research
Shares Out 58 (M)
Shares Float 57 (M)
Held by Insiders 1.7 (%)
Held by Institutions 112.6 (%)
Shares Short 12,260 (K)
Shares Short P.Month 12,400 (K)
Stock Financials
EPS -3.61
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.21
Profit Margin -78.5 %
Operating Margin -65.7 %
Return on Assets (ttm) -15.9 %
Return on Equity (ttm) -30.8 %
Qtrly Rev. Growth 31.7 %
Gross Profit (p.s.) 0
Sales Per Share 4.53
EBITDA (p.s.) -3.06
Qtrly Earnings Growth 0 %
Operating Cash Flow -111 (M)
Levered Free Cash Flow -67 (M)
Stock Valuations
PE Ratio -8.81
PEG Ratio -0.1
Price to Book value 3.11
Price to Sales 7
Price to Cash Flow -16.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android